An overview of dialysis treatment in Japan. (as of Dec. 31, 2001).

滋, 中井; 高弘, 新里; 勇爾, 奈倉; 生人, 政金; 建樹, 北岡; 俊雄, 篠田; 親雄, 山崎; 瑠実, 坂井; 浩之, 大森; 治, 守田; 邦敏, 井関; 健次郎, 菊池; 和雄, 久保; 一之, 鈴木; 薫, 田部井; 清秀, 伏見; 奈穂子, 三和; 篤志, 和田; 充, 矢内; 隆, 秋葉

doi:10.4009/jsdt.36.1

Cited by 14 publications

(10 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Japan not only has the lowest HD patient mortality rate among the 12 countries participating in the DOPPS [ 2,3 , 16 ] but also displays the most conservative anaemia management program for HD patients among these 12 countries. Anaemia management practices observed in Japan should be considered in the context of Japanese anaemia management guidelines for HD patients.…”

Section: Discussionmentioning

confidence: 99%

Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS

Akizawa

Pisoni

Akiba

et al. 2008

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Background. Japanese haemodialysis (HD) patients not only have a very low mortality and hospitalization risk but also low haemoglobin (Hb) levels. Internationally, anaemia is associated with mortality, hospitalization and health-related quality of life (QoL) measures of HD patients.Methods. Longitudinal data collected from 1999 to 2006 from 60 to 64 representative Japanese dialysis units participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS) were used to describe anaemia management practices and outcomes for Japanese HD patients.Results. From 1999 to 2006, patient mean Hb increased from 9.7 g/dl to 10.4 g/dl, and the percentage of facilities with median Hb ≥10 g/dl increased from 27% to 75%. Hb was measured in the supine position for 90% of patients, resulting in substantially lower reported Hb values than those seen in other countries. As of 2006, erythropoietin (Epo) was prescribed to 83% of HD patients; mean Epo dose was 5231 units/week; intravenous (IV) iron use was 33% and median IV iron dose was 160 mg/month. Many patient- and facility-level factors were significantly related to higher Hb. A consistent overall pattern of lower mortality risk with higher baseline Hb levels was seen (RR = 0.89 per 1 g/dl higher Hb, P = 0.003). Facilities with median Hb ≥10.4 displayed a lower mortality risk (RR = 0.77, P = 0.03) versus facility median Hb <10.4 g/dl. Lower Hb levels were not significantly related to hospitalization risk, but were associated with lower QoL scores.Conclusions. These results provide detailed information on anaemia management practices in Japan and the relationships of anaemia control with outcomes, with implications of anaemia management worldwide.

show abstract

Section: Discussionmentioning

confidence: 99%

Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS

Akizawa

Pisoni

Akiba

et al. 2008

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

show abstract

“…However, there is no evidence to support the rationality of strict glycemic control for diabetic hemodialysis patients than for nondiabetic hemodialysis patients. Rather, severe glycemic control may lead to poor prognosis of patients because of more frequent occurrence of hypoglycemic episodes, particularly in those with hypotension or hypolipidemia because of malnutrition‐inflammation‐atherosclerosis syndrome . Therefore, the improvement of nutritional status should be prioritized.…”

Section: Control Of Complicationsmentioning

confidence: 99%

Best Practice for Diabetic Patients on Hemodialysis 2012

et al. 2015

View full text Add to dashboard Cite

“…More than 200,000 patients (1,722 per million) with end-stage renal disease (ESRD) underwent maintenance renal replacement therapy in Japan in 2002. 1 In the United States, the prevalence of patients with ESRD was 1,403 per million in 2001. 2 The incidence and prevalence of ESRD, especially in diabetic and elderly patients, have been increasing over the past two decades in both countries.…”

mentioning

confidence: 99%

“…2 The incidence and prevalence of ESRD, especially in diabetic and elderly patients, have been increasing over the past two decades in both countries. 1 , 2…”

mentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular Risk Factors in Hemodialysis Patients: Results from Baseline Data of Kaleidoscopic Approaches to Patients with End-stage Renal Disease Study

Ohsawa

Kato

Itai

et al. 2005

Journal of Epidemiology

View full text Add to dashboard Cite

BACKGROUND: The prevalence of cardiovascular risk factors and the prevalence of comorbidities in adult hemodialysis patients in Japan are not fully understood. METHODS: In “Kaleidoscopic Approaches to Patients with End-stage Renal Disease Study” (The KAREN Study, 2003), trained research stuff examined 1,214 adult hemodialysis patients (mean age, 61.2 years; 779 males and 435 females) of 1,506 patients in northern areas of Iwate Prefecture. Cardiovascular risk factors and the prevalence of comorbidities in hemodialysis patients were compared with those in the general population using direct age-adjustment methodology and standardized morbidity ratios (SMRs). RESULTS: In hemodialysis patients, common causes of end-stage renal disease were chronic glomerulonephritis (29.8%), diabetic nephropathy (24.5%), and other diseases. Prevalence and SMR of myocardial infarction were 5% and 9.6, respectively, and those of stroke were 13% and 5.7. The prevalences of hypertension and diabetes mellitus were 87% and 29%, respectively. Mean systolic blood pressure and mean diastolic blood pressure were 155 mmHg and 85 mmHg, respectively. Mean levels of total serum cholesterol, high-density lipoprotein cholesterol, and albumin in patients with end-stage renal disease were lower than those of the general population (160.6 vs. 203.3 mg/dL, 48.5 vs. 59.7 mg/dL, and 3.7 vs. 4.4 g/dL, respectively). Mean levels of C-reactive protein were higher than those of the general population (3.80 vs. 1.16 mg/L). CONCLUSION: Hemodialysis patients have a high prevalence of cardiovascular risk factors and comorbidities. Levels of nutrition-related markers were lower, and C-reactive protein levels were higher, in hemodialysis patients than in the general population.

show abstract

An overview of dialysis treatment in Japan. (as of Dec. 31, 2001).

Cited by 14 publications

References 3 publications

Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS

Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS

Best Practice for Diabetic Patients on Hemodialysis 2012

Cardiovascular Risk Factors in Hemodialysis Patients: Results from Baseline Data of Kaleidoscopic Approaches to Patients with End-stage Renal Disease Study

Contact Info

Product

Resources

About